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Abstract
Background: Increased cancer risk has been reported in Parkinson’s disease (PD) patients 
carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison 
with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when 
compared with unaffected controls.
Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, 
and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic 
regression. Data were then pooled with a previous study to examine cancer risk between 401 
LRRK2-PD and 1946 IPD patients.
Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD 
patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia 
(odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 
95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of 
leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) 
when compared with IPD patients.
Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-
PD patients suggest that LRRK2 mutations heighten risks of certain cancers.
Keywords
LRRK2 gene; G2019S mutation; Parkinson’s disease; leukemia; colon cancer; pooled analysis
Although Parkinson’s disease (PD) and cancer have seemingly opposite biological 
mechanisms, recent studies indicate a potential link.1–3 Epidemiological and family-based 
studies have reported that PD patients have increased risk of melanoma4–7; however, they 
have 40% and 25% lower relative risks for smoking-related and other cancers,8,9 
respectively, when compared with the general population. Recent studies have reported 
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increased risks of various cancers among PD patients carrying leucine rich repeat kinase 2 
(LRRK2) mutations.10–15 The LRRK2 G2019S mutation, with a prevalence ranging from 
1% to 40% depending on ethnicity and age at PD onset,16 has been associated with 
increased risks of nonskin cancers11,14,15 and breast cancer,11,14,15 whereas the R1441C/G 
mutation, which has a higher prevalence in the Basque population,17 has been associated 
with colon cancer13 and hematologic cancers.10
We recently performed a pooled meta-analysis among 1549 PD patients (11.4% were 
LRRK2 G2019S carriers) and reported statistically significant increased risks of nonskin 
cancer (odds ratio [OR] = 1.62; 95% confidence interval [CI], 1.04–2.52), hormone-related 
cancers (OR = 1.87; 95% CI, 1.07–3.26), and breast cancer (OR = 2.34; 95% CI, 1.05–5.22) 
among LRRK2-PD in comparison with idiopathic PD (IPD).15 However, it is unclear 
whether the increased risk among LRRK2-PD patients would be observed when compared 
with unaffected controls who are noncarriers of the G2019S mutation.
Therefore, the goal of this analysis was to compare the prevalence of cancer outcomes 
among LRRK2-PD patients, IPD patients, and controls using a standardized questionnaire 
across several international LRRK2-PD research centers. Furthermore, we also combined 
data collected in this study with previously published data from our meta-analysis15 and 
examined the associations of LRRK2 G2019S mutation with various cancers among 2365 
PD patients.
Materials and Methods
Participants included in this analysis were 969 PD patients (257 LRRK2-PD and 712 IPD) 
and 218 genetically unrelated controls aged 35 years or older who were recruited from 7 
Michael J. Fox Foundation LRRK2 sites in Europe, Israel, and the United States. All of the 
participants completed a detailed health questionnaire, which collected information on 
demographic, lifestyle, and reproductive factors; self-reported cancer history; personal 
health-related histories; and family histories of PD and cancer. (Details about participants’ 
recruitment and data collection methodology are provided in the supporting information 
materials.) Genetic testing for LRRK2 G2019S mutation was performed in all PD patients 
and controls. Genotyping for other LRRK2 mutations: R1441G/C and I2020T was 
performed only in 2 centers in Germany and Spain. Therefore, the focus of this analysis is 
only on G2019S mutations (carriers vs. noncarriers). The study was approved by the 
respective institution review boards of all participating sites, and all participants provided 
written informed consent.
We compared demographic and lifestyle characteristics as well as prevalence of various 
cancers among LRRK2-PD patients, IPD patients, and controls using one-way analysis of 
variance models (for continuous normally distributed variables) and χ2 tests (for categorical 
variables); all tests were 2-sided (P < 0.05). The associations of various cancer outcomes 
among LRRK2-PD patients, IPD patients, and controls were examined using mixed-effect 
logistic regression to estimate ORs and 95% CIs adjusting for age, sex, and Ashkenazi 
Jewish (AJ) ethnicity as fixed effects and study center as the random effect.18 Multivariate 
models for all cancers combined, smoking-related cancers, and colon and kidney cancers 
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were additionally adjusted for smoking status and body mass index, whereas body mass 
index and reproductive factors were included in multivariate models for hormone-related 
cancers and breast cancer. We also investigated whether the associations between LRRK2 
G2019S mutation and cancer outcomes varied by ethnicity (AJ vs. others) in stratified 
analyses.19
Finally, we pooled data collected in this study with our previously published data15 and 
compared the risk of various cancers between 401 LRRK2-PD and 1964 IPD patients using 
mixed-effect logistic regression models adjusted for age, sex, and AJ ethnicity as fixed 
effects and study center (random effect). For 83 over-lapping PD patients between the 2 
datasets, the most recent data were used. We excluded 70 LRRK2-PD patients from this 
analysis who carried only the R1441G/C mutation as screening for this mutation was not 
performed in all participating centers. All statistical analyses were performed using STATA 
version 15 (College Station, TX).
Results
A total of 257 LRRK2-PD patients, 712 IPD patients, and 218 genetically unrelated controls 
aged 35 years or older were included in this analysis (Table 1). The controls were on average 
younger, more likely to be women, and less likely to be of AJ ethnicity in comparison with 
both LRRK2-PD and IPD patients. With regard to lifestyle factors, when compared with 
controls, both the LRRK2-PD and IPD patients were significantly less likely to be cigarette 
smokers and alcohol drinkers, but there was no difference in body mass index among the 3 
groups (Table 1). In comparison with female patients with LRRK2-PD or IPD, unaffected 
female controls had on average a fewer number of pregnancies (1.4 vs. 2.1 and 2.6; P < 
0.0001), and a slightly higher proportion were in menopause (94% vs. 90% and 83%; P = 
0.004).
Overall self-reported cancer prevalence was similar among LRRK2-PD patients (32.3%), 
IPD patients (27.5%), and controls (27.5%; P = 0.22; Table 1). However, the LRRK2-PD 
patients reported a higher prevalence of leukemia (1.9%) in comparison with both IPD 
patients and controls, where no leukemia was reported (P < 0.0001). Interestingly, when 
compared with IPD patients and controls, the LRRK2-PD patients also reported a higher 
proportion of multiple cancers: 8.6% vs. 6.6% and 3.7%, respectively. However, these 
differences were not statistically significant (Table 1).
Although cancer prevalence was similar among the 3 groups, the IPD patients had an overall 
lower cancer risk (OR = 0.68; 95% CI, 0.45–1.01) in comparison to controls in multivariate-
adjusted models (Table 2). With regard to specific cancers, there was a significant increased 
risk of leukemia (OR = 4.55; 95% CI, 1.46–10.61) when comparing LRRK2-PD patients to 
either the IPD patients or controls. Skin cancer was also significantly higher among the 
LRRK2-PD patients when compared with IPD patients (OR = 1.61; 95% CI, 1.09–2.37), but 
there was no difference when compared with controls (OR = 0.99; 95% CI, 0.57–1.71; Table 
2). There was also suggestive evidence of increased risks of colon and kidney cancers 
among LRRK2-PD patients; however, these associations were not statistically significant. 
Because 77% of all participants were of AJ ethnicity, we carried out a separate analysis in 
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this group; the overall results were similar to the main analysis (see Supporting Information 
Table S1).
Finally, the results of the pooled analysis (Table 3), which combined the data from this study 
with our previously published paper15 and included 401 LRRK2-PD and 1964 IPD patients, 
showed statistically significantly increased risks of leukemia (OR = 9.84; 95% CI, 2.15–
44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.72) when comparing the LRRK2-PD 
with IPD patients.
Discussion
We report the findings from a primary analysis of cancer outcomes among 257 LRRK2-PD 
patients, 712 IPD patients, and 218 unaffected controls, which used a standardized 
questionnaire to collect demographic and lifestyle factors as well as cancer outcomes across 
7 participating sites from the largest international LRRK2-PD consortium. The results 
showed that the LRRK2-PD patients had a statistically significant 4.6-fold increased risk of 
leukemia in comparison with the IPD patients and controls. In additional support, the 
findings from the pooled analysis demonstrated a stronger risk of leukemia (OR = 9.84; 95% 
CI, 2.15–44.94) when comparing LRRK2 G2019S mutation carriers with IPD patients, 
although this was based on a small number (n = 5) of leukemia reports. The observed 
positive association with leukemia in this study also supports the finding of Ruiz-Martinez 
and colleagues,10 who reported an OR = 7.1 for myeloproliferative cancers among their PD 
patients carrying the R1441G mutation. Both studies also show that IPD patients have a 
lower frequency of hematologic cancers, which has been previously reported.20,21
In our primary analysis, we also observed a 61% increased risk of nonmelanoma skin cancer 
when comparing LRRK2-PD patients with IPD patients, although in the pooled analysis the 
strength of this association was attenuated (OR = 1.36) and was no longer statistically 
significant. These findings need to be interpreted with caution as nonmelanoma skin cancers 
tend to be misreported by participants.22,23 Although LRRK2-PD patients had also 
suggestive evidence of an increased risk of colon cancer in the primary analysis (albeit not 
statistically significant because of the small numbers), in the pooled analysis we observed a 
significant 2.34-fold increased risk of colon cancer (95% CI, 1.15–4.72) when comparing 
LRRK2-PD with IPD patients. The increased risk of colon cancer has also been reported 
among PD patients with LRRK2 R1441C mutations from a large pedigree of 190 individuals 
in western Nebraska.13
Despite the associations with the specific cancers mentioned previously, we did not observe 
increased risks of hormone-related cancers and breast cancer, as reported in our previous 
study.15 Two other studies14,24 also reported increased risks of breast cancer among 
LRKK2-PD patients, and these populations were in part included in the pooled analysis. One 
of the differences is that the numbers of self-reported cancers were much lower in the 
international LRRK2-PD consortium. Moreover, the effect of LRRK2 mutations on cancer 
might vary among different populations, and other studies from Italy25 or the United 
Kingdom26 did not observe an overall increase in hormone-related cancers with LRRK2 
mutations.
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Our study has strengths and limitations that should be carefully considered. A strength is the 
use of a detailed questionnaire that collected demographic, lifestyle, and reproductive factors 
and cancer outcomes in a standardized manner, which minimized biases as a result of data 
acquisition across international LRRK2-PD centers. In addition, the pooled analysis 
included 2365 PD patients with 502 cancer outcomes collected across several sites, which 
represent the largest cohort of PD patients with genetic screening for LRRK2 mutations. 
Although self-reports of major cancers (eg, breast, prostate, colon, lung, etc.) have been 
shown to be valid and reliable,22,23,27 a limitation is that self-reported cancers from PD 
patients and controls were not validated systematically with medical records or cancer 
registry reports in participating centers. Another limitation is the relatively small sample size 
for comparisons of rare cancers among LRRK2-PD patients, IPD patients, and controls. We 
also did not have information on the tumor grades or stages for various cancers in this study, 
and because genetic associations might vary by cancer clinical phenotypes, the inclusion of 
cancer survivors might have affected the results. Finally, the potential for selection bias in 
using spouse controls and recall bias particularly among elderly PD patients as a result of the 
increased risk of dementia might have affected the results of this study. Nevertheless, the 
advantages of using spouse controls are time-and cost-efficiency and their ability to provide 
proxy lifestyle or health-related data for their affected relatives.28
In conclusion, the results of this study showed significantly increased risks of leukemia and 
colon cancer among the LRRK2-PD patients when compared with the IPD patients, which 
suggest that LRRK2 mutations can lead to multiple cancers.
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